Literature DB >> 29285730

Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.

Yevgen Ryeznik1,2, Oleksandr Sverdlov3, Andrew C Hooker4.   

Abstract

We consider optimal design problems for dose-finding studies with censored Weibull time-to-event outcomes. Locally D-optimal designs are investigated for a quadratic dose-response model for log-transformed data subject to right censoring. Two-stage adaptive D-optimal designs using maximum likelihood estimation (MLE) model updating are explored through simulation for a range of different dose-response scenarios and different amounts of censoring in the model. The adaptive optimal designs are found to be nearly as efficient as the locally D-optimal designs. A popular equal allocation design can be highly inefficient when the amount of censored data is high and when the Weibull model hazard is increasing. The issues of sample size planning/early stopping for an adaptive trial are investigated as well. The adaptive D-optimal design with early stopping can potentially reduce study size while achieving similar estimation precision as the fixed allocation design.

Keywords:  D-optimal design; Weibull distribution; adaptive design; censoring; dose finding

Mesh:

Year:  2017        PMID: 29285730     DOI: 10.1208/s12248-017-0166-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  16 in total

1.  Continual reassessment designs with early termination.

Authors:  John O'Quigley
Journal:  Biostatistics       Date:  2002-03       Impact factor: 5.899

2.  Combining multiple comparisons and modeling techniques in dose-response studies.

Authors:  F Bretz; J C Pinheiro; M Branson
Journal:  Biometrics       Date:  2005-09       Impact factor: 2.571

3.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

4.  Wide brick tunnel randomization - an unequal allocation procedure that limits the imbalance in treatment totals.

Authors:  Olga M Kuznetsova; Yevgen Tymofyeyev
Journal:  Stat Med       Date:  2013-12-03       Impact factor: 2.373

5.  Optimal response-adaptive randomized designs for multi-armed survival trials.

Authors:  Oleksandr Sverdlov; Yevgen Tymofyeyev; Weng Kee Wong
Journal:  Stat Med       Date:  2011-08-08       Impact factor: 2.373

6.  On the efficiency of two-stage response-adaptive designs.

Authors:  Holger Dette; Björn Bornkamp; Frank Bretz
Journal:  Stat Med       Date:  2012-08-03       Impact factor: 2.373

7.  Optimal experimental designs for accelerated failure time with Type I and random censoring.

Authors:  María J Rivas-López; Jesús López-Fidalgo; Rodrigo Del Campo
Journal:  Biom J       Date:  2014-07-14       Impact factor: 2.207

8.  Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes.

Authors:  Oleksandr Sverdlov; Yevgen Ryeznik; Weng-Kee Wong
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

9.  Efficiency of balanced treatment allocation for survival analysis.

Authors:  L A Kalish; D P Harrington
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

10.  RARtool: A MATLAB Software Package for Designing Response-Adaptive Randomized Clinical Trials with Time-to-Event Outcomes.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Weng Kee Wong
Journal:  J Stat Softw       Date:  2015-08-01       Impact factor: 6.440

View more
  2 in total

1.  Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Andrew C Hooker
Journal:  AAPS J       Date:  2018-07-19       Impact factor: 4.009

2.  Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations.

Authors:  Theodoros Papathanasiou; Anders Strathe; Andrew C Hooker; Trine Meldgaard Lund; Rune Viig Overgaard
Journal:  AAPS J       Date:  2018-04-23       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.